VEEV241220C220000
- 14.05
- +1.01+7.75%
Veeva Systems Newsroom
Barclays Maintains Veeva Systems(VEEV.US) With Buy Rating, Maintains Target Price $260
Barclays Reaffirms Their Buy Rating on Veeva Systems (VEEV)
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)
Veeva Systems Analyst Ratings
Scotiabank Initiates Coverage On Veeva Systems With Sector Perform Rating, Announces Price Target of $235
William Blair Maintains Veeva Systems(VEEV.US) With Buy Rating
Veeva Systems: Strong Market Position and Future Growth Potential Drive Buy Rating
BTIG Maintains Veeva Systems(VEEV.US) With Buy Rating, Raises Target Price to $280
BTIG Maintains Veeva Systems(VEEV.US) With Buy Rating, Raises Target Price to $280
BTIG Remains a Buy on Veeva Systems (VEEV)
Jefferies Maintains Veeva Systems(VEEV.US) With Buy Rating, Raises Target Price to $280
Baird Maintains Veeva Systems(VEEV.US) With Buy Rating, Raises Target Price to $275
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veeva Systems (VEEV) and Neuren Pharmaceuticals Limited (OtherNURPF)
A Quick Look at Today's Ratings for Veeva Systems(VEEV.US), With a Forecast Between $230 to $280
Veeva Systems Analyst Ratings
Veeva Systems Is Maintained at Outperform by RBC Capital
A Quick Look at Today's Ratings for Veeva Systems(VEEV.US), With a Forecast Between $260 to $280
Veeva Systems (VEEV) Receives a Buy From Barclays
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Veeva Systems (VEEV)
Needham Reiterates Buy on Veeva Systems, Maintains $260 Price Target